# Evaluation of Safety and Efficacy of Symbicort® pMDI, With or Without Spacer, in Children (6-11 Years) With Asthma

> **NCT00536913** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 107 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Budesonide/formoterol pMDI 40/2.25ug + spacer
- **DRUG:** Budesonide/formoterol pMDI 40/2.25 ug

## Key facts

- **NCT ID:** NCT00536913
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2012-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00536913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00536913, "Evaluation of Safety and Efficacy of Symbicort® pMDI, With or Without Spacer, in Children (6-11 Years) With Asthma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00536913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*